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Background: Hypermethylation of the promoter region of the RAS association domain family 1A gene (RASSF1A)
occurs widely in hepatocellular carcinoma (HCC) tissues. While the diagnostic performance of the use of RASSF1A
methylation as a serum or plasma marker in patients with HCC has varied largely in the literature,we confirmed the
clinical application value of serum RASSF1A methylation for HBV related HCC in this study.
Methods: A total of 584 participants were recruited into this study, including 190 patients with HCC, 114 patients
with liver cirrhosis (LC), 120 patients with chronic hepatitis B (CHB) and 160 healthy individuals. Serum RASSF1A
methylation was determined by the MethyLight method. In addition, we followed up 43 HCC patients who were
unable to undergo surgery for 24 months.
Results: Serum RASSF1A methylation occurred significantly more frequently in patients with HCC (122/190, 64.2 %)
than in patients with LC (20/114, 17.5 %), patients with CHB (6/120, 5.0 %) and in healthy individuals (0/160, 0)
(P < 0.001); moreover, it allowed for the discrimination of patients with HCC from those with CHB with an areas under
the ROC curves (AUC) of 0.796 (64.2 % sensitivity and 89.8 % specificity). Furthermore, the AUC for the combination of
serum RASSF1A methylation and AFP level (≥20 ng/L) was 0.876 (80.9 % sensitivity and 93.4 % specificity). Serum
RASSF1A methylation positive in patients with HCC was associated with more malignant clinical characteristics and a
worse overall survival (OS) (P < 0.05).
Conclusion: Serum RASSF1A methylation demonstrated a satisfactory value for in the diagnosis of HBV related HCC,
and could predict clinical progression and prognosis. In addition, our findings suggested that the combination of
serum RASSF1A methylation and AFP level may be a promising non-invasive biomarker for the discrimination of
patients with HCC from those with CHB.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_DPAT-D-15-00090.1
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HCC (Hepatocellular carcinoma, HCC) is one of the
high incidence and mortality malignant tumors in the
world. Chronic hepatitis B virus (HBV) infection is an
important etiological factor of HCC in Southeast Asia.
The estimated overall HBV carrier prevalence among
Chinese aged 1 to 59 years was 9.75 %, and the prevalence
in difference provinces in China ranged from 4.49 to
17.85 %, which has led to a large number of individuals
who are at risk for HCC [1]. At present, a serum α-
fetoprotein (AFP) assay is widely used, but it has a rela-
tively low sensitivity and specificity, and thus its clinical
value is limited. Depending on currently clinical diagnostic
tools, the patients with HCC may not undergo the most
effective treatment as most of them have already pro-
gressed to advanced stages by the time they are diagnosed.
Therefore, there is an urgent need for the identification of
effective diagnostic and prognostic biomarkers for HCC.
Aberrant DNA methylation is one of the most com-
mon characteristics of malignant cells. Some tumor sup-
pressor genes and other pivotal genes that regulate cell
signaling pathways are frequently silenced due to the
promoter methylation in tumor tissues; these changes
have been tested and shown to be sensitive and specific
markers for HCC [2–4]. However, the use of tumor tis-
sues to test for promoter methylation is invasive and
thus impractical for HCC screening in high-risk popula-
tions. Several studies have shown that the detection of
DNA promoter methylation in serum or plasma is highly
consistent with its presence in tumor tissues [5], which
suggests that the gene promoter methylation in the
serum might be a promising non-invasive biomarker for
tumor diagnosis.
The RAS association domain family 1A gene (RASSF1A)
is a tumor suppressor gene that is located in the 3p21.3 re-
gion and is an important member of the RAS signaling
pathway. It plays a critical role in apoptosis cell cycle,
microtubule stability, cell adhesion and migration [6]. The
RASSF1A gene has been concerned and studied inten-
sively for its tumor suppression, and hypermethylation in
the promoter region is suspected as the main mechanism
of silencing that is observed widely in human malignan-
cies, including HCC tissues [7, 8]. Although its diagnostic
value in serum, plasma or the other body fluids of patients
with HCC has been studied, large discrepancies exist in
regards to its diagnostic performance, such as the sensitiv-
ity (0.27 to 0.94) and specificity (0.38 to 0.95) [9].
The aim of this study was to explore whether the pro-
moter methylation status of RASSF1A as detected by
MethyLight assay is altered in the serum of patients with
HBV-related HCC compared with age- and gender-
matched patients with chronic hepatitis B (CHB), liver
cirrhosis (LC) and healthy individuals. In addition, we
evaluated the potential relationship between serumRASSF1A methylation status and the clinicopathologi-
cal features and overall survival (OS) of patients with
HCC. Finally, we assessed whether serum RASSF1A
methylation was a satisfactory biomarker for HCC pa-
tients with chronic HBV infection.
Methods
Subjects
A total of 584 participants who visited Hangzhou First
People’s Hospital from June 2011 to June 2013 were en-
rolled in this study. They were divided into four age-
and gender-matched groups (HCC, LC, CHB patients
and healthy subjects). In all, 190 patients with HCC had
been diagnosed by serum AFP level, liver ultrasound,
computed tomography (CT), and magnetic resonance
imaging (MRI). Those who met the diagnostic criteria
for HCC, which was confirmed by histological examin-
ation were enrolled. These HCC patients had not re-
ceived any preoperative radiotherapy or chemotherapy.
114patients with LC were diagnosed by liver ultrasound,
CT, and MRI, and exhibited accompanying portal hyper-
tension and hypersplenism. 120 patients with CHB met
the diagnostic criteria based on the guidelines for the
prevention and treatment of chronic hepatitis B (2010
version) by the Chinese Society of Hepatology and Chin-
ese Society of Infectious Diseases of the Chinese Medical
Association, and did not have LC and HCC as detected by
liver ultrasound. 160 healthy individuals were obtainde
from Physical Examination Center of Hangzhou First Peo-
ple’s Hospital.
In addition, the patients with HCC, LC and CHB were
HBV surface antigen (HBsAg)-positive in the serum, and
had not undergone anti-viral treatment. The participants
who presented with other liver diseases, such as auto-
immune hepatitis, alcoholic hepatitis and other types of
hepatitis virus infections were excluded from this study.
The study protocol was approved by the Ethics Commit-
tee of Hangzhou First People’s Hospital.
Serum samples collection and DNA extraction
Two milliliters of serum was isolated after centrifugation
at 3000 rpm for 10 min and was then centrifuged at
12,000 rpm for 5 min. One milliliter of serum was isolated
carefully and stored at −80 °C until use. Serum DNA was
extracted by a serum DNA extraction kit (GenMagBio
Biotechnology Co., Ltd., Beijing, China) following the
protocol recommended by the manufacturer.
Sodium bisulfite modification
Serum DNA was modified by sodium bisulfite treatment
and purified using the EpiTect Bisulfite Kit (Qiagen,
Hilden, Germany) following the protocol recommended
by the manufacturer.
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The methylation status of RASSF1A was examined using
methylation-specific quantitative PCR (MethyLight). The
modified DNA samples were amplified with specific
primers and Taqman probes. The sequences of the
primers and probes for RASSF1A and β-actin (ACTB)
were previously described [10, 11]. The PCR mixture
contained 1 μl bisulfite-treated DNA, 0.15 μl of each pri-
mer (10 uM), 0.1 μl of each probe (10 uM), 9.6 μl
nuclease-free water, and 10.0 μl 2 × PCR Buffer (Toyobo
Co., Ltd, Japan), which consisted of Taq DNA polymer-
ase, reaction buffer, and a deoxynucleotide triphosphate
mixture, in a final volume of 20 μl. The PCR was per-
formed for RASSF1A and ACTB in parallel in an ABI
7500 Sequence Detection System (Life Technologies,
USA). The PCR program included an initial denatur-
ation step at 95 °C for 3 min, followed by 45 cycles of
denaturation at 95 °C for 10 s, and annealing at 60 °C
for 1 min. Genomic DNA from healthy individuals,
which was treated with SssI methylase and sodium
bisulfite in vitro, was used as a positive control. DNA
from healthy human blood was used as a negative
control. Water without DNA served as a control for
contamination was included in each assay. Serum
RASSF1A methylation is presented as the Percentage
Methylated Reference (PMR) [12]. A PMR ≥ 4 %
would be classified as positive, while a PMR < 4 %
would be classified as negative; these values have
been validated in the literature as the standard cut-off
values [13–16].
Statistical analysis
The Mann–Whitney test was used to study the differences
in the non-parameter variables. The Correlation between
serum RASSF1A methylation and clinicopathologic
parameters was determined using the χ2 test. Overall
survival analysis was performed with the Kaplan-MeierTable 1 The baseline clinical data of 584 subjects
Characteristics HCC (n = 190) LC
Age (y) 52.32 ± 18.63 54
Male 136 (71.58) 76
ALT (U/L) 62.82 ± 46.27 71
ALB (g/L) 33.39 ± 14.57 30
TBIL (μmol/L) 26.54 ± 19.83 76
PLT (×109/μL) 15.65 ± 13.07 11
HBeAg (+) 96 (50.52) 60
HBV DNA (log10 copies/mL) 5.93 ± 1.86 5.7
AFP (≥20 ng/L) 118 (62.11) 62
There were significant differences in the levels of ALT, ALB, TBIL, PLT and AFP in the
deviation or n (%)
HCC hepatocellular carcinoma, LC liver cirrhosis, CHB chronic hepatitis B; ALT alanine
HBV e-antigen, AFP α-fetoproteinanalysis and log-rank test Receiver-operating-characteristic
(ROC) curves were constructed and the areas under the
ROC curves (AUCs) were calculated to determine the
feasibility of using serum RASSF1A methylation and/or
AFP level as a biomarker for HCC. A value of P < 0.05
was considered statistically significant. Data analyses




The baseline characteristics of the enrolled participants
are shown in Table 1. Of those, the serum levels of ala-
nine aminotransferase (ALT) and total bilirubin (TBIL)
were obviously higher in cases of HCC, LC and CHB
compared with the healthy controls (P < 0.05), whereas
the albumin (ALB) and platelet (PLT) levels were higher
in the healthy controls (P < 0.05). The frequency of a
serum AFP level ≥20 ng/L was highest in patients with
HCC followed by patients with CHB and patients with
LC (P <0.05).
Methylation status of RASSF1A in the serum
Methylation of RASSF1A in the serum was detected in
122 of 190 (64.2 %) from patients from the HCC group,
in 20 of 114 (17.5 %) patients from the LC group and in
6 of 120 (5.0 %) patients from the CHB group, but no
methylation of RASSF1A was detected in the healthy
controls. The rate of serum RASSF1A methylation in
patients with HCC patients was significantly higher than
that in patients with LC or CHB patients (P < 0.001) Fig. 1.
Evaluation of serum RASSF1A methylation as a potential
HCC diagnostic marker for HCC
To further investigate the diagnostic value of serum
RASSF1A methylation in HCC, ROC curves were con-
structed. Serum RASSF1A methylation discriminated(n = 114) CHB (n = 120) Health (n = 160)
.65 ± 15.39 54.65 ± 15.33 52.12 ± 16.76
(66.67) 84 (70.00) 110 (68.75)
.19 ± 32.40 90.81 ± 60.23 24.62 ± 16.28
.18 ± 11.95 38.13 ± 8.26 40.13 ± 4.67
.49 ± 42.35 50.28 ± 46.03 9.81 ± 6.73
.36 ± 9.81 16.85 ± 13.49 19.04 ± 10.27
(52.63) 68 (56.67) 0 (0)
8 ± 1.29 5.87 ± 1.13 0
(54.39) 32 (26.67) 0 (0)
HCC, LC and CHB groups (P < 0.05). All data are presented as mean ± standard
aminotransferase, ALB albumin, TBIL total bilirubin, PLT blood platelet, HBeAg
Fig. 1 The rate of positive serum RASSF1A methylation in the HCC, LC, CHB and healthy control groups. The positive rate was 64.2 % (122/190),
17.5 % (20/114), 5.0 % (6/120) and 0 (0/160), respectively; P * < 0.01 versus CHB; P ** < 0.001 versus LC, CHB
Fig. 2 Receiver operating characteristic (ROC) curve analyses using serum RASSF1A methylation and AFP for the discrimination of patients with
HCC from patients with CHB. Positive serum RASSF1A methylation yielded an AUC of 0.796 (95 % CI: 0.721–0.864) with a sensitivity of 64.2 % and
a specificity of 89.8 % for the discrimination of patients with HCC from patients with CHB; serum AFP at the cut-off value (≥20 ng/mL) yielded an
AUC of 0.756 (95 % CI: 0.652–0.805) with a sensitivity of 62.1 % and a specificity of 80.7 %; combined, both indicators yielded an AUC of 0.876
(95 % CI: 0.781–0.933) with a sensitivity of 80.9 % and a specificity of 93.4 %
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(95 % CI = 0.721–0.864), the sensitivity and specificity for it
was 64.2 and 89.8 %, respectively. The serum AFP at the
cut-off value of 20 ng/mL yielded an AUC of 0.756
(95 % CI = 0.652–0.805) with a sensitivity of 62.1 % and a
specificity of 80.7 %. Furthermore, the AUC for the combin-
ation of both indicators was 0.876 (95 % CI = 0.781–0.933),
the sensitivity 80.9 % and specificity at 93.4 % Fig. 2.
Methylation and clinicopathological characteristics in HCC
patients
The association between serum RASSF1A methylation
and the clinicopathological characteristics of HCC was
assessed (Table 2). Some of the clinical parameters, such
as histological grading, tumor stage and portal venous
invasion were significantly related to serum RASSF1A
methylation (P < 0.05). However, no significant relation-
ship was observed between serum RASSF1A methylation
and the other parameters, such as serum HBeAg status,
tumor number, tumor size and liver cirrhosis (P > 0.05).
Serum RASSF1A methylation status and survival of HCC
patients
Forty-three HCC patients were unable to undergo surgi-
cal operation in this study, which were followed up forTable 2 Correlation between serum RASSF1A methylation status an
Characteristics Case (n = 190) RASSF1A
HBeAg
Positive 96 (50.5) 71 (58.2)
Negative 94 (49.5) 51 (41.8)
Tumor number
Single 128 (67.4) 84 (68.9)
Multiple 62 (32.6) 38 (31.1)
Tumor size
< 5 cm 92 (48.4) 50 (41.0)
≥ 5 cm 98 (51.6) 72 (59.0)
Histological grading
I + II 134 (70.5) 69 (56.6)
III + IV 56 (29.5) 53 (43.4)
TNM stage
I + II 68 (35.8) 26 (21.3)
III + IV 122 (64.2) 96 (78.7)
Portal venous invasion
Yes 122 (64.2) 62 (50.8)
No 68 (35.8) 60 (49.2)
Liver cirrhosis
Yes 118 (62.1) 64 (52.5)
No 72 (37.9) 58 (47.5)
All data are presented as n (%)
HCC hepatocellular carcinoma, HBeAg HBV e-antigen24 months completely. These patients were divided into
the positive group (n = 24) and the negative group (n = 19)
according to the PMR of serum RASSF1A promoter. The
patients with serum RASSF1A methylation were more
likely to have worse OS according to the Kaplan–Meier
analysis (P < 0.05) (Fig. 3).
Discussion
Aberrant promoter methylation of the tumor suppressor
RASSF1A leads to many malignancies, which indicates
that it plays an important role in the development of hu-
man cancer [17]. Down-regulation of RASSF1A expres-
sion was unrelated to some conventional etiologies, such
as HBV / HCV infection, alcohol consumption, and food
aflatoxin B1 contamination [3], which suggested that the
inactivation of RASSF1A may be a common event in
HCC development. Some studies have reported that the
rate of RASSF1A methylation was up to 85, 95 and
100 % in HCC tissues, [18–20]. In addition, Hu [21] has
shown that reduced of RASSF1A protein expression was
related to clinicopathological features of HCC patients
with regard to TNM stage, AFP level, tumor metastasis
and presence of multiple nodules. These data suggested
that RASSF1A methylation may be a promising non-
invasive biomarker for HCC. However, the results ofd clinico-pathological features of HCC [n (%)]








Fig. 3 Kaplan–Meier analysis of the overall survival (OS) of 43 patients with HCC. Forty-three patients with HCC were followed-up for 25 months. A
Kaplan–Meier analysis showed that patients with HCC with serum RASSF1A positivity (n= 24) were more likely to experience a worse OS (P = 0.017)
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city of RASSF1A methylation in peripheral blood of
HCC patient have been so varied [9]; this phenomenon
may be attributed to the detection methods or the sam-
ple size, and therefore its non-invasive application value
for HCC needs to be further confirmed.
In this study, we used the MethyLight method to de-
tect serum RASSF1A methylation in a larger sample,
and when the PRM ≥4 the result is positive. We found
that the rate of serum RASSF1A methylation in HCC
patients was significantly higher than that in LC or CHB
patients; however, no RASSF1A methylation was de-
tected in healthy subjects. Currently, the serum AFP
level (≥20 ng/L) is widely used in the distinction of HCC
from CHB, and the diagnostic sensitivity and specificity
were 62.1 and 80.7 % in this study, respectively. In the
same way, serum RASSF1A methylation yielded a sensi-
tivity of 64.2 % and specificity of 89.8 %, which were
prior to AFP level (≥20 ng/L). When RASSF1A methyla-
tion and serum AFP are used in combination to distin-
guish HCC from CHB, the sensitivity and specificity are
inceased to 80.9 and 93.4 %, respectively. This result
indicates that both indicators combined would be a bet-
ter marker for HCC in HBV prevalence region. Through
an analysis of the relationship between the RASSF1Amethylation status and the clinicopathological features
of HCC patients, we found that serum RASSF1A methy-
lation was associated with higher histological grading,
tumor stage and the occurrence of portal venous inva-
sion. This result suggested that serum RASSF1A methy-
lation positive could predict the clinical progression of
HCC patients.
In addition, we conducted 2 years of follow-up study
in 43 patients who were not treated with surgery. Our
results showed that the OS of patients with serum
RASSF1A methylation was significantly lower than that
of the patients without RASSF1A methylation. Circulat-
ing free DNA may result from the formation of circu-
lating tumor cells or DNA fragments generated by
tumor cell necrosis and apoptosis [22, 23]. This hy-
pothesis implies that serum RASSF1A methylation may
originate in circulating tumor cells, which then leads to
tumor metastasis.
Conclusion
In conclusion, serum RASSF1A methylation may be a
valid biomarker for HBV-related HCC and could predict
clinical progression. Specifically, the combination of serum
RASSF1A methylation and the AFP level could strengthen
the power of discrimination of HCC and CHB.
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